These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19284362)

  • 21. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic lymphoma kinase inhibitors.
    Crescenzo R; Inghirami G
    Curr Opin Pharmacol; 2015 Aug; 23():39-44. PubMed ID: 26051994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovering novel chemotherapeutic drugs for the third millennium.
    Garrett MD; Workman P
    Eur J Cancer; 1999 Dec; 35(14):2010-30. PubMed ID: 10711243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
    Abbaspour Babaei M; Kamalidehghan B; Saleem M; Huri HZ; Ahmadipour F
    Drug Des Devel Ther; 2016; 10():2443-59. PubMed ID: 27536065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor tyrosine kinase inhibitors: Are they real tumor killers?
    Gaumann AK; Kiefer F; Alfer J; Lang SA; Geissler EK; Breier G
    Int J Cancer; 2016 Feb; 138(3):540-54. PubMed ID: 25716346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Targeted therapy for cancer: anti-tyrosine kinase receptor agents].
    García ED
    An R Acad Nac Med (Madr); 2007; 124(1):171-84; discussion 184-8. PubMed ID: 18069612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond.
    Bologna M; Vicentini C; Muzi P; Pace G; Angelucci A
    Curr Med Chem; 2011; 18(19):2827-35. PubMed ID: 21651496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
    Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
    Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
    Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
    Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
    Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor tyrosine kinases as target for anti-cancer therapy.
    Brunelleschi S; Penengo L; Santoro MM; Gaudino G
    Curr Pharm Des; 2002; 8(22):1959-72. PubMed ID: 12171522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
    Tolmachev V; Stone-Elander S; Orlova A
    Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid Compounds as Multitarget Directed Anticancer Agents.
    Kucuksayan E; Ozben T
    Curr Top Med Chem; 2017; 17(8):907-918. PubMed ID: 27697050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.
    Mazitschek R; Giannis A
    Curr Opin Chem Biol; 2004 Aug; 8(4):432-41. PubMed ID: 15288254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FAK inhibitors in Cancer, a patent review.
    Lv PC; Jiang AQ; Zhang WM; Zhu HL
    Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.